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Article focus
  To investigate the influence of calcium 
release from bioresorbable devices in rela-
tion to bone healing since the clinical ben-
efits of calcium phosphate (CaP) additives 
to these devices over normal fracture 
repair times have not been established.
  We investigated the ability of surface 
treatment of bioresorbable polymer 
devices (via electron beam treatment) to 
accelerate calcium (Ca) release in vitro 
and the biological response in vivo in an 
orthotopic model.
Key messages
  ebeam (eB) treatment accelerated in 
vitro release of CaP dissolution products 
from clinically relevant polymer screws 
to a timeframe relevant to normal frac-
ture repair.
enhanced release of calcium phosphate 
additives from bioresorbable orthopaedic 
devices using irradiation technology is 
non-beneficial in a rabbit model 
aN aNimal sTudy
Objectives
Bioresorbable orthopaedic devices with calcium phosphate (cap) fillers are commercially 
available on the assumption that increased calcium (ca) locally drives new bone formation, 
but the clinical benefits are unknown. electron beam (eB) irradiation of polymer devices has 
been shown to enhance the release of ca. The aims of this study were to: 1) establish the 
biological safety of eB surface-modified bioresorbable devices; 2) test the release kinetics 
of cap from a polymer device; and 3) establish any subsequent beneficial effects on bone 
repair in vivo.
Methods
Activascrew Interference (Bioretec Ltd, Tampere, Finland) and poly(L-lactide-co-glycolide) 
(pLGA) orthopaedic screws containing 10 wt% β-tricalcium phosphate (β-Tcp) underwent 
eB treatment. In vitro degradation over 36 weeks was investigated by recording mass loss, 
pH change, and ca release. Implant performance was investigated in vivo over 36 weeks 
using a lapine femoral condyle model. Bone growth and osteoclast activity were assessed by 
histology and enzyme histochemistry.
Results
calcium release doubled in the eB-treated group before returning to a level seen in untreated 
samples at 28 weeks. extensive bone growth was observed around the perimeter of all 
implant types, along with limited osteoclastic activity. no statistically significant differences 
between comparative groups was identified.
Conclusion
The higher than normal dose of eB used for surface modification did not adversely affect 
tissue response around implants in vivo. surprisingly, incorporation of β-Tcp and the sub-
sequent accelerated release of ca had no significant effect on in vivo implant performance, 
calling into question the clinical evidence base for these commercially available devices.
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  eB-treated polymers had no detrimental effect on the 
biological response.
  enhanced Ca release did not increase bone formation 
or osteoclast activity in vivo.
strengths and limitations
  strength: In vitro and in vivo comparative results.
  limitation: animal model limited to two timepoints.
introduction
The use of bioresorbable fixation devices in orthopaedic 
surgery began in the mid-1980s to treat displaced frac-
tures of the ankle.1 They are seen as advantageous over 
their metallic counterparts because devices degrade 
gradually during healing, limiting the stress shielding 
associated with rigid metallic devices that has been 
shown to result in osteoporosis.2 also, the potential need 
for future device removal is negated.3 Recently, there has 
been much interest in the incorporation of therapeutic 
additives, such as an antibiotic-releasing bioresorbable 
fixation device,4 and there are a number of calcium phos-
phate (CaP)-containing devices.5
despite this promise, issues surrounding the degrada-
tion of implantable bioresorbable polymer devices have 
limited their success. Poly(α-hydroxy acids) are the most 
widely investigated bioresorbable polymers due to their 
tailorable degradation properties and excellent biocom-
patibility; they include poly(lactic acid), poly(glycolic 
acid) and a range of poly(l-lactic-co-glycolide) copoly-
mers.6 degradation of these polymers proceeds via 
hydrolysis of ester bonds,7 which results in the release of 
monomer and oligomer degradation products. if this 
hydrolytic degradation is slow compared with diffusion, 
the complete cross-section of the polymer matrix is 
affected as there is ample water available for hydrolysis, a 
process known as bulk degradation.8 if acidic degrada-
tion products build up in the polymer matrix and acceler-
ate hydrolysis, in a process known as autocatalysis,9 they 
can become trapped within the device, and erosion of 
the polymer surface can then result in sudden release of 
these products.8 it was a degradation-related failure that 
led to the 2007 recall of the Calaxo interference screw 
(smith & Nephew plc, london, united Kingdom).10
Furthermore, this pattern of degradation has a signifi-
cant impact on the release profile of any products incor-
porated within the polymer matrix, as release rate is 
closely related to degradation.11 There are a number of 
clinically available bioresorbable polymer and ceramic 
composite interference screws including Bilok 
(Biocomposites ltd., Keele, united Kingdom), Biosteon 
(stryker Corp., Kalamazoo, michigan), Biosure Ha and 
Regenesorb (smith & Nephew, mansfield, massachusetts), 
BioComposite (arthrex GmbH, munich, Germany), 
Genesys matryx (Conmed Corp., utica, New york), 
ComposiTCP (Zimmer Biomet inc., Warsaw, indiana), 
and milagro (dePuy synthes, Raynham, massachusetts). 
These devices are widely used and display appropriate 
degradation times,12-16 however, the evidence base sup-
porting claims of enhanced clinical performance is weak, 
and questions remain around the clinical significance of 
adding osteoconductive materials to bioresorbable 
screws.17
in order to improve long-term mechanical properties 
and additive release profiles, surface degradation should 
be initiated prior to bulk degradation, permitting bulk 
strength retention while allowing the release of additives 
from the surface.18 This can be achieved through the use 
of low-energy electron beam (eB) radiation. This emerg-
ing technology has seen applications in semiconductor 
manufacture and food security (food-safe packaging and 
microbial inactivation) but has never been utilized by 
the medical device industry for use in clinical products. 
Potentially, bioresorbable medical devices, such as inter-
ference screws, suture anchors, fracture fixation plates, 
and bone fixation screws, could be treated with eB to 
ensure surface degradation occurs ahead of bulk degrada-
tion, thereby ensuring the release of surface-encapsulated 
therapeutics in a timely manner. such therapeutics may 
include antimicrobials (e.g. antibiotics) and minerals that 
are essential to bone healing such as calcium (Ca), phos-
phorous, zinc, and silicon. eB irradiation would typically 
be applied at higher doses than those used for medical 
sterilization, thus causing near-surface polymer chain 
scission, and decreasing molecular weight and accelerat-
ing the surface degradation process. In vitro studies have 
shown it to be suitable for medical-grade polymer sur-
face modification and controlled additive release due to 
its low and tailorable penetration capability,19-23 but the 
safety of neither the higher dose, nor the increased sur-
face degradation, has yet been confirmed in vivo.
The aims of this study were to investigate eB treatment 
as a method of enhancing the release of CaP dissolution 
products from clinically relevant orthopaedic screws and 
to assess the effect on in vivo performance. a rabbit femo-
ral condyle defect model was chosen as the bone is large 
enough to accommodate implantation of commercially 
available screws in a clinically relevant anatomical loca-
tion; many of these polymer screws are designed for liga-
ment repair around the knee joint.
Materials and Methods
Commercial interference screws formulated from a pro-
prietary blend of poly(l-lactide-co-glycolide) (PlGa) 
(activascrew interference; Bioretec ltd, Tampere, 
Finland) and prototype screws of the same formulation 
with additional 10 wt% β-tricalcium phosphate (β-TCP; 
PlGa-TCP) were provided by Bioretec ltd. a total of 31 
PlGa and 31 PlGa-TCP screws were eB-treated using an 
eBlab electron beam laboratory unit (Comet aG, Flamatt, 
switzerland), and equal numbers remained untreated. eB 
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treatment entailed a bilateral surface dosage of 500 kGy 
and an accelerating voltage of 115 kev, giving an all-
round penetration depth of approximately 50 μm (as 
simulated by Comet’s eBlab software). all screws were 
then sterilized by γ-irradiation (25 kGy) in a single batch.
In vitro analysis. dissolution was assessed in vitro by mon-
itoring mass and pH changes, and Ca release from the 
PlGa-TCP screws. screws were weighed to the nearest 
0.1 mg, placed individually in 30 ml phosphate-buffered 
saline (PBs) solution in sealed containers, and stored at 
37°C with no agitation. Timepoints were 4, 12, and 36 
weeks, with four treatment groups (PlGa, PlGa+eB, 
PlGa-TCP, PlGa-TCP+eB), and n = 5 for each out-
come measure. The mean starting masses of the screws 
were: PlGa = 3.250 g (sd 0.046); PlGa+eB = 3.270 g 
(sd 0.040); PlGa-TCP = 3.260 g (sd 0.019); and PlGa-
TCP+eB = 3.267 g (sd 0.023), giving an approximate 
mass:volume ratio of 1:10.
at each timepoint, screws were dried under vacuum at 
ambient temperature to a constant mass, which was then 
recorded. dissolution media pH was measured using an 
Hi-2210 Basic pH Benchtop meter with an Hi-1131B 
General Purpose laboratory pH electrode (both Hanna 
instruments ltd, leighton Buzzard, united Kingdom). 
The pH was measured weekly for the first four weeks, and 
every two weeks thereafter. Calcium release from the 
PlGa-TCP screws was quantified by inductively coupled 
plasma mass spectroscopy (iCP-ms) (elaN dRC-e; Perkin-
elmer ltd, seer Green, united Kingdom) with a detecting 
limit of 0.04 mg/l. Calcium was quantified in a 2 ml sam-
ple removed from the test container at two weeks, four 
weeks, and every four weeks thereafter up to 36 weeks, 
and cumulative Ca release was calculated.
In vivo analysis. In vivo screw performance was assessed 
using a New Zealand White rabbit model. all rabbits 
(Thrush Hall supplies, Co. antrim, united Kingdom) 
were female, 28 to 30 weeks old, skeletally mature 
with a mean weight of 3.7 kg (sd 0.32). all procedures 
had ethical approval, were performed under a licence 
issued by the department of Health, social services and 
Public safety of Northern ireland, and were carried out 
in accordance with the regulations as laid down in the 
uK animals (scientific Procedures) act 1986. a total of 
32 rabbits underwent surgery and received implants 
bilaterally in the distal femoral condyles, giving 64 exper-
imental samples in total, and eight samples per experi-
mental condition per timepoint. implantation sites were 
randomly assigned an implant type (PlGa, PlGa+eB, 
PlGa-TCP or PlGa-TCP+eB). Rabbits were sacrificed 
at 12 weeks and 36 weeks post-implantation. animals 
assigned to the later timepoint were operated on first but 
otherwise implant order was randomized. a power calcu-
lation showed that eight animals per group would allow 
us to detect an effect size of an increase in percentage 
bone area of 10% with 80% power.
The surgical procedure was similar to that used by 
Palmer et al.24 Rabbits were anaesthetized using Hypnorm 
(vetaPharma ltd, leeds, united Kingdom), intramuscu-
larly, at 0.25 ml/kg, and midazolam (Hypnovel; Roche 
Products ltd, Welwyn Garden City, united Kingdom), 
intravenously, at 0.5 mg/kg to 1.5 mg/kg25,26. an incision 
(approximately 2 cm) was made medially to the patella, 
allowing lateral dislocation of the patella. The femoral 
condyle was visualized and a defect slightly smaller than 
the size of a screw was created by reaming with a cus-
tom-made handheld steel drill. The slow speeds involved 
meant that there was minimal heat generation, and, prior 
to implantation, the defect was lavaged with a saline 
solution to remove any debris from the cavity. The 
implant was then screwed into place using the supplied 
driver so that the base of the screw was flush with the 
cortical bone before the patella was reduced. all implants 
were fitted correctly. The incision was closed in two lay-
ers using bioresorbable sutures (Coated vicryl; ethicon 
inc., livingston, united Kingdom). Post-surgery, rabbits 
were given a broad-spectrum antibiotic (Baytril; Bayer 
HealthCare aG, leverkusen, Germany) at 2 ml/kg subcu-
taneously and an analgesic (Temgesic; Reckitt & Colman 
PlC, Hull, united Kingdom) subcutaneously at 0.5 ml/kg 
mixed 1:9 with saline solution. animals were weight 
bearing within approximately two to three hours and had 
access to food and water ad libitum. animals were sacri-
ficed with a lethal intravenous injection of sodium pento-
barbital (euthatal; merial animal Health ltd, Woking, 
united Kingdom).
at sacrifice, femora were cleaned of soft tissue, fixed in 
4 wt% paraformaldehyde (sigma-aldrich Co., Gillingham, 
united Kingdom) in PBs for two days at 4°C, then dehy-
drated through graded alcohols, cleared in xylene 
(sigma-aldrich), and embedded in a poly(methyl meth-
acrylate) (Pmma)-based resin (Technovit 9100 Neu; 
Heraeus Kulzer GmbH, Wehrheim, Germany) according 
to the manufacturer’s instructions. embedded specimens 
were sectioned using an accutom-50 precision cut-off 
machine (struers ltd, Rotherham, united Kingdom). 
longitudinal sections of 300 µm thickness were mounted 
on fully frosted microscope slides (Fisherfinest; Fisher 
scientific uK, loughborough, united Kingdom). sections 
were then polished with an alpha 2 speed Grinder/
Polisher fitted with a vector Power Head (both Buehler, 
Coventry, united Kingdom) prior to staining.
a section from the centre of each implant showing a 
complete cross-section was stained with a 0.25% w/v 
Toluidine Blue (TolBlue) solution (sigma-aldrich), then 
rinsed with water and allowed to air dry before viewing. 
a second section from each implant was used for enzyme 
histochemistry to stain for tartrate-resistant acid phos-
phatase (TRaP), a commonly used technique for the 
detection of osteoclasts. Prior to staining, resin was 
removed from the sections by soaking in acetone 
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(sigma-aldrich). sections were adhered to fresh slides 
and rehydrated through graded alcohols to distilled 
water. The staining solution was prepared from a kit 
(acid Phosphatase, leukocyte; sigma-aldrich) according 
to the manufacturer’s instructions, then covered in an 
aqueous-based permanent mounting medium (CC/
mount; sigma-aldrich) and dried at 70°C.
Both TolBlue- and TRaP-stained sections were viewed 
under a Nikon smZ800 stereomicroscope (Nikon uK ltd, 
Kingston upon Thames, united Kingdom). using 
Photoshop CC (adobe systems europe ltd, maidenhead, 
united Kingdom) and blind to the experimental group, a 
Region of interest (Roi) was drawn 0.8 mm around the 
perimeter of the implant, and the percentage of bone in 
this area was measured. To quantify TRaP activity, the 
sections were divided into two areas: within 500 µm of 
the implant and more than 500 µm from the edge of the 
implant. The number of TRaP-stained pixels in each area 
of the sections was labelled as 0 (no TRaP activity), 1 (low 
TRaP activity), or 2 (moderate TRaP activity).
statistical analysis. one-way analysis of variance 
(aNova) was used to identify significant differences 
between groups with pairwise comparisons using Tukey's 
honestly significant difference tests to assess intergroup 
differences, provided the sample sizes were the same. 
if assumptions of aNova were not met, Kruskal–Wallis 
multiple comparisons stepwise stepdown analysis was 
performed. all statistical analyses were performed using 
PasW statistics 18.0 (iBm Corp., armonk, New york). a 
p-value of ⩽ 0.05 was considered significant.
Results
as expected from bioresorbable polymers, there was a 
trend towards decreasing mass over in vitro dissolution 
time (Fig. 1). after four weeks, no significant mass 
changes were observed in any group or between groups 
(p = 0.654). after 12 weeks, both eB-treated groups 
showed a statistically significant reduction in mass when 
compared with the initial screw mass and the screw mass 
after four weeks of dissolution. This was not the case in 
the untreated groups, which showed no significant mass 
change. The largest mass changes were observed after 36 
weeks. Between groups, the eB treatment resulted in a 
significantly greater mass loss in both the PlGa and the 
PlGa-TCP screws. screws at 12 weeks were visually com-
pared after drying (Fig. 2). shrinkage cracks occurred 
during the drying process for the PlGa+eB group screws, 
but surface cracking was not apparent for the non-treated 
PlGa screws. surface cracking was not obvious for the 
PlGa-TCP+eB group, however, they appeared distinctly 

























Time (wks) 4 12 36
Fig. 1
Percentage mass change over dissolution time for the four screw groups 
(n = 5; mean (sd); * p < 0.05). PlGa, poly(l-lactide-co-glycolide); eB, elec-






optical microscopy images of screws following 12 weeks of in vitro degra-
dation. a) PlGa; b) PlGa+eB; c) PlGa-TCP; d) PlGa-TCP+eB. PlGa, poly(l-
lactide-co-glycolide); eB, electron beam; TCP, tricalcium phosphate.
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differences in pH between treated and untreated sam-
ples were apparent from around four weeks (Fig. 3). eB 
treatment accelerated the drop in pH of PlGa+eB sam-
ples to 7.4 at ten weeks, while the pH of PlGa samples 
remained relatively constant. The difference in pH 
between treated and untreated PlGa samples continued 
to increase, reaching 7.3 and 7, for PlGa and PlGa+eB, 
respectively, by 22 weeks. a similar trend is seen in the 
TCP-containing samples, although slightly delayed com-
pared with the PlGa only.
marked differences in Ca release were observed 
between PlGa-TCP and PlGa-TCP+eB (Fig. 4). after two 
weeks, the amount of Ca released is similar for untreated 
and treated samples, however between weeks 4 and 24, 
significantly more Ca was released from the eB-treated 
samples (p < 0.001). at each timepoint between four 
and 24 weeks, Ca release increased by over 100% follow-
ing eB treatment. From 28 weeks onwards, the effect of 
eB treatment on Ca release was less marked.
Before surgery, all rabbits were in good health and 
were given at least seven days of acclimatization. all ani-
mals tolerated the procedure well with no adverse events 
and no gross pathology upon implant retrieval. during 
processing for histological analysis, three implants were 
lost, one from the 36-week PlGa+eB group and two 
from the 36-week PlGa group. due to the technical chal-
lenges of removing the resin while retaining section 
integrity before TRaP staining, the numbers per group 
were reduced for this outcome measure. The exact num-
ber per group is provided in the relevant figure legend.
in general, the implants were well tolerated in vivo, 
with evidence of new bone growth and little indication of 
inflammatory response. By 36 weeks, in approximately 
one-third of cases in every treatment group, cracking of 
the screws was evident with bone growth into the cracks 
(Fig. 5). There was no significant difference in the amount 




















































Calcium (Ca) release over dissolution time for the two tricalcium phosphate 
(TCP)-containing screw groups (n = 4; mean (sd)). PlGa, poly(l-lactide- 
co-glycolide); eB, electron beam.
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either timepoint (Fig. 6). Within the treatment groups, 
significant decreases in percentage of bone in the Roi 
were observed between 12 and 36 weeks in both the 
PlGa and the PlGa-TCP+eB groups (p = 0.004 and 
p = 0.038, respectively). No significant change over time 
was observed in the PlGa+eB or the PlGa-TCP groups 
(p > 0.999 and p = 0.798, respectively).
more TRaP activity was observed in the 12 weeks 
group compared with the 36 weeks group (Fig. 7). more 
TRaP activity was also observed within 500 µm of the 
implants than in regions further away from the implants. 
No differences in TRaP were apparent between treated 
and untreated samples or between TCP-containing sam-
ples and PlGa only samples.
Discussion
eB irradiation has been used in other industries and has 
potential to be applied to the medical device industry as 
it has been shown to enhance the release of additives to 
bioresorbable polymers. The aims of this study were to 
establish the safety of eB treatment on clinically relevant 
orthopaedic devices in an orthotropic model and to iden-
tify any clinical benefit in the form of enhanced bone 
growth associated with the use of CaP as a bioactive.
The in vitro mass loss study showed that screws from 
all groups largely retained their original mass after four 
weeks of dissolution, and untreated screws retained their 
mass after 12 weeks. This is in line with reported times for 
typical onset of PlGa degradation ranging from 14 weeks 
to 22 weeks, depending on the l-lactide residual mono-
mer content.27 The eB treatment had the anticipated 
effect of accelerating degradation as evidenced by the 
significant mass loss associated with both PlGa+eB and 
PlGa-TCP+eB in comparison with the untreated sam-
ples. This was supported by the observed shrinkage 
cracks for the vacuum-dried PlGa+eB at 12 weeks, indi-
cating a decrease in surface volume. Changes in pH of 
this system can be attributed to either polymer break-
down, releasing oligomers of acidic nature, or dissolution 
of TCP, of basic nature (i.e. tends to cause a pH increase). 
The divergence in pH values between the eB- and non-
eB-treated screw types at four to 26 weeks is associated 
with more rapid surface polymer breakdown for the eB 
groups whereas, beyond 26 weeks, differences are likely 
to be a result of a pH-buffering effect associated with the 
release of TCP from the polymer.28
The idea that differences in mass loss and pH between 
TCP-containing screws and PlGa-only screws were a 
result of a buffering effect associated with dissolution of 
TCP was confirmed by measuring the Ca released from 
the screws. it has been shown that the incorporation of 
Ca compounds delays PlGa degradation with the basic-
ity of Ca compounds proportional to the delay.29 Calcium 
release from eB-treated samples was at least double that 
observed in untreated samples between four and 24 
weeks, and almost 200% greater at eight and 12 weeks. 
This increased Ca release coincides with typical healing 
times of common fractures where bioresorbable screws 
may be clinically deployed.30 However, PlGa-TCP com-
posites have been shown to degrade more rapidly under 
dynamic conditions.31
In vivo results demonstrate that there was no detri-
mental effect of eB treatment on the biological response 
to the screws. There was no significant difference in bone 
formation nor any inflammatory response found in the 



























Time (wks) 12 36
Fig. 6
Percentage of bone in the perimeter region of interest (Roi) surrounding the 
implants from each group after 12 and 36 weeks’ implantation (n = 8, apart 
from PlGa and PlGa+eB at nine months where n = 6 and n = 7, respectively; 









Toluidine Blue (TolBlue)-stained section showing typical host response to 
an implanted screw (PlGa-TCP after 36 weeks in this instance), with bone 
ingrowth into cracks indicated with * and highlighted in the magnified area of 
interest. PlGa, poly(l-lactide-co-glycolide); TCP, tricalcium phosphate.
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In vitro, 12 weeks was one of the timepoints that showed 
the largest effect of eB treatment on Ca release, yet there 
was no significant difference between implant types in 
vivo. Therefore, we did not detect an effect of Ca release 
on in vivo performance.
In vitro results showed that, by 36 weeks, there was 
significant mass loss, between approximately 25% and 
45%, observed in all groups by this timepoint. There 
were similar levels of Ca release across all treatment 
groups and a convergence of pH between the PlGa-
TCP and PlGa-TCP+eB groups. Therefore, we did not 
expect to see, nor did we see, any significant difference 
in bone growth around the implants between treat-
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PLGA PLGA+EB PLGA-TCP PLGA-TCP+EB
36 wks
TRAP activity 2 1 0
Fig. 7b
a) and b) Percentage of samples displaying tartrate-resistant acid phosphatase (TRaP) activity both within, and further than 500 μm from the implants after 12 
and 36 weeks. The TRaP activity was quantified on an arbitrary scale of 0 (no TRaP activity), 1 (low TRaP activity), or 2 (moderate TRaP activity). n = 7 (PlGa 
12 weeks, PlGa+eB 12 weeks, PlGa-TCP 12 weeks); n = 5 (PlGa-TCP+eB 12 weeks, PlGa 36 weeks, PlGa-TCP 36 weeks); n = 4 (PlGa+eB 36 weeks); n = 8 
(PlGa-TCP+eB 36 weeks). PlGa, poly(l-lactide-co-glycolide); eB, electron beam; TCP, tricalcium phosphate.
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PlGa- and TCP-containing screws was expected, given 
the osteoconductive nature of β-TCP but this hypothe-
sis was not supported by our results, and all implant 
types were well tolerated.
similarly, the presence of Ca resulted in no clear differ-
ences in the level of TRaP activity between pure PlGa- 
and TCP-containing samples, regardless of eB treatment. 
The TRaP activity is a marker for osteoclast activity, and 
thus, this finding suggests that the presence of β-TCP did 
not significantly stimulate osteoclast activity around the 
implants in this model. The reduction in TRaP activity 
over time is likely to be due to waning of initial trabecular 
bone repair.
There are few studies comparing in vivo outcomes 
associated with TCP incorporation into bioresorbable 
polymers. incorporation of 60% β-TCP into poly-l-lactic 
acid (Plla) has been shown to cause less inflammatory 
reaction and to promote osteogenesis in a rabbit model 
when compared with pure Plla.32 a polycaprolactone 
(PCl)/PlGa scaffold with incorporated β-TCP resulted in 
significantly greater bone density compared with a PCl/
PlGa scaffold without β-TCP in a rabbit model,33 and 
PlGa fibres containing 40% amorphous TCP resulted in a 
significantly increased fraction of newly formed bone in a 
non-critically sized rabbit calvarial defect model com-
pared with PlGa alone34 but we were unable to replicate 
these effects in this model. This is perhaps due to the 
lower level of TCP addition and lower surface-to-volume 
ratio in our study. a randomized controlled trial compar-
ing milagro (30% β-TCP in PlGa) and Calaxo (PlGa + 
35% calcium carbonate) screws in anterior cruciate liga-
ment (aCl) reconstruction surgery indicated that inclu-
sion of osteoconductive materials into PlGa screws was 
not associated with bone formation at the screw site at 
up to two years.17 These clinical results agree with our 
experimental model, and highlight the current lack of rel-
evant evidence of the benefits of TCP incorporation into 
aCl screws.
The bone response to bioresorbable polymers is com-
plex and can be related to a number of factors such as 
absorption rate, material, age, sex, and health of the 
patient and the device’s location in the body.35,36 adding 
osteoconductive materials adds further variables with 
their varied absorption profiles. modelling this complex-
ity in the rabbit obviously has limitations and the choice 
of timepoint can be crucial. We chose 12 and 36 weeks as 
timepoints that would be able to show enhanced healing 
around the implant and enhanced long-term resorption 
of the implant, respectively. We cannot rule out the pos-
sibility that an effect of Ca may have been measurable 
earlier in the healing, however, it could be argued that 
the clinical significance of this may be limited if the effect 
was not maintained at 12 weeks.
in conclusion, eB treatment allows early surface degra-
dation of bioresorbable polymer devices. For the first time, 
we have shown that pretreatment of device surfaces can 
significantly increase the early release rate of incorpo-
rated therapeutic agents without adversely affecting bio-
logical response. incorporation of β-TCP into the polymer 
formulation under investigation did not influence in vivo 
performance over the timescales investigated in a rabbit 
model, even after accelerating Ca release through eB 
treatment. although the evidence does not support the 
clinical use of CaP-containing bioresorbable devices, the 
ability to control and accelerate the release of therapeutic 
additives is a valuable tool. Therefore, the technology has 
potential for use in future orthopaedic device develop-
ment, where beneficiary additives may include antimicro-
bials (such as antibiotics) and mineral components.
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